- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Anavex Life Sciences Corp (AVXL)
Anavex Life Sciences Corp stock price live, this page displays NASDAQ AVXL stock exchange data. View the AVXL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Anavex Life Sciences Corp real time stock price chart below.
What Is the Anavex Life Sciences Corp Stock Price Today?
The Anavex Life Sciences Corp stock price today is 9.680.
What Is the Stock Symbol for Anavex Life Sciences Corp?
The stock symbol for Anavex Life Sciences Corp is ""AVXL.""
What Stock Exchange Does Anavex Life Sciences Corp Trade On?
Anavex Life Sciences Corp is listed and trades on the NASDAQ stock exchange.
Is Anavex Life Sciences Corp a Good Stock to Buy?
Determining whether Anavex Life Sciences Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AVXL quote. (ISIN: US0327973006)
What Is the Anavex Life Sciences Corp Stock Price Today?
The Anavex Life Sciences Corp stock price today is 9.680.
What Is the Stock Symbol for Anavex Life Sciences Corp?
The stock symbol for Anavex Life Sciences Corp is ""AVXL.""
What Stock Exchange Does Anavex Life Sciences Corp Trade On?
Anavex Life Sciences Corp is listed and trades on the NASDAQ stock exchange.
Is Anavex Life Sciences Corp a Good Stock to Buy?
Determining whether Anavex Life Sciences Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AVXL quote. (ISIN: US0327973006)
NASDAQ
Currency in USD
Fair Value
An estimate of a Anavex Life Sciences's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.310
9.720
52 wk Range
4.930
14.441
AVXL Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
AVXL is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Anavex Life Sciences's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.3109.720
52 wk Range
4.93014.441
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AVXL Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Anavex Life Sciences's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
34.333
Upside
+254.68%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral
Anavex Life Sciences Corp Company Profile
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company’s ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against the Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Anavex Life Sciences Corp Earnings Call Summary for Q3/2025
- Q3 2025 net loss of $13.2M ($0.16/share), missing EPS forecast; R&D expenses down $1.8M YoY; admin costs up to $4.5M
- Strong cash position of $101.2M with no debt; shares fell 1.15% to $11.22 in premarket trading
- Anticipating EMA feedback in Q1 next year; preparing for UK filings; exploring orphan indications and EU commercialization
- CEO emphasized early Alzheimer's treatment; company focusing on rare disease studies and European market strategies
- Risks include rising admin costs, regulatory uncertainties, market competition, and dependence on successful trial outcomes
Last Updated: 12/08/2025, 14:20
Read Full TranscriptCompare AVXL to Peers and Sector
Metrics to compare | AVXL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAVXLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −17.3x | −3.0x | −0.6x | |
PEG Ratio | 1.30 | 0.02 | 0.00 | |
Price/Book | 9.1x | 1.8x | 2.6x | |
Price / LTM Sales | - | 8.6x | 3.3x | |
Upside (Analyst Target) | 347.3% | 200.3% | 39.5% | |
Fair Value Upside | Unlock | 4.3% | 4.9% | Unlock |
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 34.333
(+254.68% Upside)
Earnings
Latest Release
Aug 12, 2025
EPS / Forecast
-0.16 / -0.1457
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Anavex Life Sciences Trade On?
Anavex Life Sciences is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Anavex Life Sciences?
The stock symbol for Anavex Life Sciences is "AVXL."
What Is the Anavex Life Sciences Market Cap?
As of today, Anavex Life Sciences market cap is 833.17M.
What Is Anavex Life Sciences's Earnings Per Share (TTM)?
The Anavex Life Sciences EPS (TTM) is -0.57.
When Is the Next Anavex Life Sciences Earnings Date?
Anavex Life Sciences will release its next earnings report on 21 Dec 2025.
From a Technical Analysis Perspective, Is AVXL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Anavex Life Sciences Stock Split?
Anavex Life Sciences has split 2 times.
How Many Employees Does Anavex Life Sciences Have?
Anavex Life Sciences has 42 employees.
What is the current trading status of Anavex Life Sciences (AVXL)?
As of 21 Aug 2025, Anavex Life Sciences (AVXL) is trading at a price of 9.68, with a previous close of 9.44. The stock has fluctuated within a day range of 9.31 to 9.72, while its 52-week range spans from 4.93 to 14.44.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.